Clinical trials
Portal Vein Thrombosis clinical trials
Below are recruiting portal vein thrombosis clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06513780Recruiting
Liver transplant and portal vein blood clot study
This study looks at how blood clots in the portal vein (the main vein to your liver) affect recovery and outcomes after a liver transplant. If you've had a liver transplant, your data may help doctors understand this better.
BeijingAges 18 years+ - NCT05782556Recruiting
Freiburg TIPS Registry for portal hypertension patients
This is a registry study that collects information from people who need a procedure called TIPS for portal hypertension. It may help doctors better understand outcomes and care for both cirrhotic and non-cirrhotic causes of portal hypertension.
Freiburg im BreisgauAges 18–100 - NCT06960954Recruiting
Testing a blood marker for liver cancer blood clots
This study looks at whether a substance in the blood called PIVKA-II can predict blood clots in the main vein of the liver (portal vein) in people with liver cancer. Participating could help doctors better identify who might develop this complication.
Tanta, GharbyeaAges 18 years+ - NCT07461532Recruiting
Apixaban for late portal vein clot after spleen surgery
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
Yangzhou, JiangsuAges 18 years+ - NCT07461545Recruiting
Apixaban for late portal vein clot after spleen surgery
This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.
Yangzhou, JiangsuAges 18 years+ - NCT07473375Recruiting
Factors affecting portal vein clot reopening in cirrhosis
This study looks at factors that help open up blood clots in the main vein to the liver (portal vein) in people with cirrhosis and varices. It might help guide treatment to improve blood flow.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07521332RecruitingPhase 4
Testing Apixaban to Prevent Bleeding Complications in Cirrhosis
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
Hyderābād, SindhAges 18 years+ - NCT07310316Recruiting
A trial for variceal bleeding in cavernous transformation of portal vein
This study tests a combined procedure to stop bleeding from enlarged veins in the food pipe (varices) in people with a rare condition called cavernous transformation of the portal vein. The treatment involves blocking the bleeding veins and reducing blood flow to the spleen to prevent future bleeding.
Xi'an, ShaanxiAges 18–75 - NCT06823375RecruitingPhase 2
Radiation plus immunotherapy for liver cancer with major vein clot
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hong KongAges 18 years+ - NCT07122089RecruitingPhase 2
SIRT plus immunotherapy for liver cancer with portal vein clot
This trial tests a two-step approach for liver cancer that has spread into the portal vein. First, you receive internal radiation (SIRT) to shrink the tumor, followed by immunotherapy drugs (durvalumab with or without tremelimumab) to help your immune system fight the cancer. The goal is to see if this combination is safe and effective.
GrenobleAges 18 years+ - NCT07132515RecruitingPhase 4
Blood thinners for cirrhosis with portal vein clot
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
Al Mansurah, Dakahlia GovernorateAges 18–70 - NCT06166576RecruitingPhase 2
Radioembolization for Liver Cancer with Vein Involvement
This trial tests a targeted radiation treatment (radioembolization) for liver cancer that has grown into the main vein (portal vein) but is still limited to one lobe of the liver. It is for people who have not received any prior cancer treatment and whose liver function is still fairly good.
Ilsan, Gyeonggi-doAges 18 years+ - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT03368651RecruitingPhase 3
Testing a pre-surgery infusion to improve liver cancer outcomes
This trial tests whether giving medicine directly into the liver blood vessels before surgery can improve survival for people with liver cancer that has a blockage (tumor in the portal vein). It compares this approach plus surgery versus surgery alone in a randomized study.
Guangzhou, GuangdongAges 18–75 - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT04868149RecruitingPhase 3
Laparoscopic versus open ALPPS to regrow liver before surgery
This study compares two ways of doing a staged liver surgery (ALPPS) to help regrow enough liver for people with certain liver cancers. It looks at outcomes and how well the remaining liver grows after surgery, using different surgical approaches.
Hong KongAges 18 years+ - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT05882370RecruitingPhase 2
Immunotherapy plus TIPS for liver cancer with blocked portal vein
This study tests whether adding the immunotherapy drug cadonilimab (and a related treatment plan) plus TIPS can help people with advanced liver cancer that has a tumor clot causing portal vein pressure problems. It aims to improve disease control while managing the circulation pressure in the liver.
Guangzhou, GuangdongAges 18–75
Hear when a new Portal Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for portal vein thrombosis?
- Yes. Clin2 currently lists 18 recruiting portal vein thrombosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a portal vein thrombosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a portal vein thrombosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.